Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: Implications on pharmacokinetics and drug toxicities.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current drug metabolism

• Publication date

  2009-09-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/138920009790274531PMID 20214582
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy.

  2009cited by this paper
• Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.

  2009cited by this paper
• siRNA and Innate Immunity

  2009cited by this paper
• The promises and pitfalls of RNA-interference-based therapeutics

  2009cited by this paper
• Knocking down barriers: advances in siRNA delivery

  2009cited by this paper
• Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors

  2009cited by this paper
• Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse.

  2009cited by this paper
• Multifunctional and stimuli-sensitive pharmaceutical nanocarriers.

  2009cited by this paper
• In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

  2009cited by this paper
• Antibody-modified liposomes for cancer chemotherapy

  2008cited by this paper
• Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer.

  2008cited by this paper
• Molecular-targeted therapies: lessons from years of clinical development.

  2008cited by this paper
• Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.

  2008cited by this paper
• Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.

  2008cited by this paper
• Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.

  2008cited by this paper
• Nonviral Nanoscale-Based Delivery of Antisense Oligonucleotides Targeted to Hypoxia-Inducible Factor 1α Enhances the Efficacy of Chemotherapy in Drug-Resistant Tumor

  2008cited by this paper
• Thermo-responsive systems for controlled drug delivery.

  2008cited by this paper
• Intra and Inter-Molecular Interactions Dictate the Aggregation State of Irinotecan Co-Encapsulated with Floxuridine Inside Liposomes

  2008cited by this paper
• Preclinical Manufacture of Anti‐HER2 Liposome‐Inserting, scFv‐PEG‐Lipid Conjugate. 2. Conjugate Micelle Identity, Purity, Stability, and Potency Analysis

  2008cited by this paper
• Delivery Vehicles for Small Interfering RNA In Vivo

  2008cited by this paper
• Preclinical Manufacture of an Anti‐HER2 scFv‐PEG‐DSPE, Liposome‐Inserting Conjugate. 1. Gram‐Scale Production and Purification

  2008cited by this paper
• A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes.

  2008cited by this paper
• Enhanced therapeutic effects on the multi‐drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine

  2008cited by this paper
• Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA.

  2008cited by this paper
• Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.

  2007cited by this paper
• Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility.

  2007cited by this paper
• Interfering with disease: a progress report on siRNA-based therapeutics

  2007cited by this paper
• Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.

  2007cited by this paper
• Optimizing combination chemotherapy by controlling drug ratios.

  2007cited by this paper
• pH‐Sensitive liposomes‐principle and application in cancer therapy

  2007cited by this paper
• A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines.

  2006cited by this paper
• Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats.

  2006cited by this paper
• Effect of stealthy liposomal topotecan plus amlodipine on the multidrug‐resistant leukaemia cells in vitro and xenograft in mice

  2006cited by this paper
• Transition Metal-Mediated Liposomal Encapsulation of Irinotecan (CPT-11) Stabilizes the Drug in the Therapeutically Active Lactone Conformation

  2006cited by this paper
• Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2)

  2006cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• Antitumor activity of doxorubicin encapsulated in hexadecylphosphocholine (HePC) liposomes against human xenografts on Scid mice.

  2006cited by this paper
• Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

  2006cited by this paper
• Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.

  2006cited by this paper
• Copper-topotecan complexation mediates drug accumulation into liposomes.

  2006cited by this paper
• Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.

  2006cited by this paper
• Phase III study of PSC‐833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95)

  2006cited by this paper
• Sphingolipids in cancer: Regulation of pathogenesis and therapy

  2006cited by this paper
• Systemic Delivery of Liposomal Short-Chain Ceramide Limits Solid Tumor Growth in Murine Models of Breast Adenocarcinoma

  2005cited by this paper
• Chemosensitization and Radiosensitization of Tumors by Plant Polyphenols

  2005cited by this paper
• Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates

  2005cited by this paper
• Cytotoxicity of flavonoids toward cultured normal human cells.

  2005cited by this paper
• In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells.

  2005cited by this paper
• Tumor-specificity and apoptosis-inducing activity of stilbenes and flavonoids.

  2005cited by this paper
• Cell-Specific Targeting of Lipid-Based Carriers for ODN and DNA

  2005cited by this paper
• Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.

  2005cited by this paper
• The liposomal formulation of doxorubicin.

  2005cited by this paper
• Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA

  2005cited by this paper
• Bimodal effect of hypoxia in cancer: role of hypoxia inducible factor in apoptosis.

  2004cited by this paper
• Encapsulation of naturally occurring flavonoids into liposomes: physicochemical properties and biological activity against human cancer cell lines

  2004cited by this paper
• Biologically active sphingolipids in cancer pathogenesis and treatment

  2004cited by this paper
• Development of ligand-targeted liposomes for cancer therapy

  2004cited by this paper
• From the bench to the bedside: ways to improve rituximab efficacy.

  2004cited by this paper
• In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading

  2004cited by this paper
• Monoclonal antibodies as therapeutic agents for cancer.

  2004cited by this paper
• Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks

  2004cited by this paper
• Gene therapy clinical trials worldwide 1989–2004—an overview

  2004cited by this paper
• Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine

  2004cited by this paper
• Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis.

  2004cited by this paper
• Simultaneous Modulation of Multidrug Resistance and Antiapoptotic Cellular Defense by MDR1 and BCL-2 Targeted Antisense Oligonucleotides Enhances the Anticancer Efficacy of Doxorubicin

  2003cited by this paper
• The role of p53 in chemosensitivity and radiosensitivity

  2003cited by this paper
• Toxicity and disposition of TLC ELL-12 (liposomal antitumor ether lipid) in Sprague-Dawley rats

  2003cited by this paper
• Monoclonal antibody therapy for cancer.

  2003cited by this paper
• High ceramide content liposomes with in vivo antitumor activity.

  2003cited by this paper
• HER‐2‐Targeted Antisense Oligonucleotide Results in Sensitization of Head and Neck Cancer Cells to Chemotherapeutic Agents

  2003cited by this paper
• Ligand-targeted therapeutics in anticancer therapy

  2002cited by this paper
• Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

  2002cited by this paper
• Formation of transition metal-doxorubicin complexes inside liposomes.

  2002cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• Tumor-targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 Levels

  2002cited by this paper
• The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors.

  2001cited by this paper
• Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

  2001cited by this paper
• Enzyme-activated targeting of liposomes.

  2001cited by this paper
• In vivo applications of PEG liposomes: unexpected observations.

  2001cited by this paper
• Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.

  2001cited by this paper
• Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer.

  2001cited by this paper
• Phototriggering of liposomal drug delivery systems.

  2001cited by this paper
• Liposomal bleomycin: increased therapeutic activity and decreased pulmonary toxicity in mice.

  2001cited by this paper
• The MRP family and anticancer drug metabolism.

  2001cited by this paper
• A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.

  2001cited by this paper
• Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.

  2000cited by this paper
• Current status of pH-sensitive liposomes in drug delivery.

  2000cited by this paper
• Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer

  2000cited by this paper
• Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles.

  2000cited by this paper
• A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model.

  2000cited by this paper
• Dietary Antioxidants During Cancer Chemotherapy: Impact on Chemotherapeutic Effectiveness and Development of Side Effects

  2000cited by this paper
• Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.

  2000cited by this paper
• Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling.

  1999cited by this paper
• The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).

  1999cited by this paper
• Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.

  1999cited by this paper
• Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models.

  1999cited by this paper
• Future developments in the selectivity of anticancer agents: Drug delivery and molecular target strategies

  1998cited by this paper
• Hydration of polyethylene glycol-grafted liposomes.

  1998cited by this paper
• In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.

  1998cited by this paper
• Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids.

  1998cited by this paper

• A convenient protonated strategy for constructing nanodrugs from hydrophobic drug-inhibitor conjugates to reverse tumor multidrug resistance.

  2024cites this paper
• Development of Nanostructured Lipid Carriers for Donepezil Hydrochloride Effective Nose to Brain Delivery

  2024cites this paper
• Redox-responsive drug-inhibitor conjugate encapsulated in DSPE-PEG2k micelles for overcoming multidrug resistance to chemotherapy.

  2023cites this paper
• Research Progress of Conjugated Nanomedicine for Cancer Treatment

  2022cites this paper
• A Brief Review on Advantages of Nano-based Drug Delivery Systems

  2021cites this paper
• Safety and Toxicity Issues of Therapeutically Used Nanoparticles from the Oral Route

  2021cites this paper
• Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue

  2021cites this paper
• Reduction of 5-fluorouracil-induced toxicity by Sarcodon aspratus polysaccharides in Lewis tumor-bearing mice.

  2020cites this paper
• The role of artificial intelligence in scaling nanomedicine toward broad clinical impact

  2020cites this paper
• Floxuridine-chlorambucil conjugate nanodrugs for ovarian cancer combination chemotherapy.

  2020cites this paper
• Studies on interaction potency model based on drug synergy and therapeutic potential of triple stimuli-responsive delivery of doxorubicin and 5-fluoro-2-deoxyuridine against lymphoma using disulfide-bridged cysteine over mesoporous silica nanoparticles.

  2020cites this paper
• Toxicity Consideration of Carbon Nanotubes

  2019cites this paper
• Carbon Nanotubes for Targeted Drug Delivery

  2019cites this paper
• Hepatoprotective Effect of Carboxymethyl Pachyman in Fluorouracil-Treated CT26-Bearing Mice

  2017cites this paper
• Development of a boronic acid sensor-based glucose-responsive nanoparticulate insulin delivery system

  2017cites this paper
• Solid Lipid Nanoparticles of Albendazole for Enhancing Cellular Uptake and Cytotoxicity against U-87 MG Glioma Cell Lines

  2017cites this paper
• Cross-Linked Dependency of Boronic Acid-Conjugated Chitosan Nanoparticles by Diols for Sustained Insulin Release

  2016cites this paper
• Biolabile peptidyl delivery systems toward sequential drug release

  2016cites this paper
• Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.

  2016cites this paper
• Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer.

  2015cites this paper
• Synergistic Combination Chemotherapy of Camptothecin and Floxuridine through Self-Assembly of Amphiphilic Drug-Drug Conjugate.

  2015cites this paper
• Mucoadhesive Chitosan Derivatives as Novel Drug Carriers.

  2015cites this paper
• Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation

  2015cites this paper
• Application of polymeric nanoparticles and micelles in insulin oral delivery

  2015cites this paper
• Safety and toxicity concerns of orally delivered nanoparticles as drug carriers

  2015cites this paper
• Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging.

  2015cites this paper
• Advances in combination therapies based on nanoparticles for efficacious cancer treatment: an analytical report.

  2015cites this paper
• Liposomal codelivery of a synergistic combination of bioactive lipids in the treatment of acute myeloid leukemia.

  2014cites this paper
• Anticancer Drug-Incorporated Layered Double Hydroxide Nanohybrids and Their Enhanced Anticancer Therapeutic Efficacy in Combination Cancer Treatment

  2014cites this paper
• Development of a gradient high performance liquid chromatography assay for simultaneous analysis of hydrophilic gemcitabine and lipophilic curcumin using a central composite design and its application in liposome development.

  2014cites this paper
• Managing diabetes with nanomedicine: challenges and opportunities

  2014cites this paper
• Potentials of polymeric nanoparticle as drug carrier for cancer therapy: with a special reference to pharmacokinetic parameters.

  2014cites this paper
• Platinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural Factor

  2013cites this paper
• Nanocarriers for anticancer drugs--new trends in nanomedicine.

  2013cites this paper
• Nanoparticles‐Based Carriers for Gene Therapy and Drug Delivery

  2013cites this paper
• Role of integrated cancer nanomedicine in overcoming drug resistance.

  2013cites this paper
• Combination anticancer nanopreparations of novel proapoptotic drug, TRAIL and siRNA

  2013cites this paper
• Ligand-Based Targeting of Therapeutic and Imaging Agents for Cancer

  2013cites this paper
• Toxicity Studies of Poly(Anhydride) Nanoparticles as Carriers for Oral Drug Delivery

  2012cites this paper
• In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia.

  2012cites this paper
• A systems approach to uncovering the adaptive response of cancer to targeted therapies

  2012cites this paper
• Nanoparticle-based combination therapy toward overcoming drug resistance in cancer.

  2012cites this paper
• Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances.

  2012cites this paper
• Regenerative medicine.

  2011cites this paper
• Multilayer coating of gold nanoparticles (AuNP) with drug-polymer complex: Development and characterization

  2011cites this paper
• Nanoscale delivery systems for multiple drug combinations in cancer.

  2011cites this paper
• Cancer cell invasion: treatment and monitoring opportunities in nanomedicine.

  2011cites this paper
• Biamphiphilic triblock copolymer micelles as a multifunctional platform for anticancer drug delivery.

  2011cites this paper
• Recent Advancement of Chitosan-Based Nanoparticles for Oral Controlled Delivery of Insulin and Other Therapeutic Agents

  2011cites this paper
• Increased ERK activation and cellular drug accumulation in the enhanced cytotoxicity of folate receptor-targeted liposomal carboplatin.

  2011cites this paper
• Nanoparticles in oncology: the new theragnostic molecules.

  2011cites this paper
• Anticancer activity of an extract from needles and twigs of Taxus cuspidata and its synergistic effect as a cocktail with 5-fluorouracil

  2011cites this paper
• Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma

  2010cites this paper